Missed Out on Novo Nordisk Stock? Buy This 1 Biotech Stock Right Now

After rising by 137% in one day upon the publication of favorable phase 2 clinical trial results on Feb. 27, Viking Therapeutics (VKTX 10.60%) is now doubtlessly on many investors' radars. Soon enough, the biotech will likely try to launch a new weight loss medication capable of rivaling Novo…#novonordisk #vikingtherapeutics #wegovy #elililly #zepbound #fda
Source: Reuters: Health - Category: Consumer Health News Source Type: news